Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?

Key Takeaways KROS is advancing KER-065 for DMD, with FDA orphan drug status and a phase II trial planned for early 2026.DYN reported positive data for z-rostudirsen, showing dystrophin gains and functional improvements in DMD.DYN held $791.9M in cash as of Sept. 2025, funding operations into Q3 2027, alongside multiple programs.Keros Therapeutics (KROS) is a clinical-stage biopharmaceutical company developing innovative therapies for patients with disorders caused by abnormal signaling within the transform ...